Assay.Works and 2bind Partner to Expand Lead Discovery Services

Combining expertise in functional bioassays and molecular interaction studies with High Throughput Screening (HTS) capabilities creates a comprehensive service portfolio supporting Drug Discovery programs.
 
1 2 3
Partnership
Partnership
REGENSBURG, Germany - Oct. 17, 2018 - PRLog -- Assay.Works GmbH (Assay.Works), the experts for bioactivity assay and high-throughput screening (HTS) services and 2bind GmbH (2bind), the specialist CRO for molecular interaction studies and biophysical assays today announced a partnership significantly expanding the range of lead discovery services offered to clients in the pharmaceutical and biotech industry, and academic organizations.

HTS is a well-established methodology for identifying new lead compounds for drug discovery and chemical biology. Molecular interaction studies are ideally suited to elucidate the molecular mechanism of hit compounds derived from HTS. A combination of HTS, high quality compound libraries, and an understanding of the mechanism of action facilitates the identification and prioritization of unique and tractable starting points for drug discovery programs.

The agreement gives Assay.Works access to 2bind's extensive experience with molecular interaction studies for hit identification, validation, and characterization. Biophysical assay technologies include MicroScale Thermophoresis (MST), nano-scale Differential Scanning Fluorimetry (nanoDSF), Biolayer Interferometry (BLI), and Isothermal Titration Calorimetry (ITC).

2bind's clients will benefit from Assay.Works' broad range of cell-based and biochemical assay capabilities combined with extensive experience in HTS and assay automation. 2bind gains access to 384-well format screening and nanoliter dispensing instrumentation, libraries totaling 150.000 small molecules and 97.000 siRNAs, and a portfolio of assay cell lines.

As part of the agreement, the companies share common laboratory and administrative premises at the BioPark Regensburg. The co-localization facilitates seamless interaction, scientific exchange, and efficiency gains via sharing infrastructure and laboratory equipment.

Dr. Ralf Schwandner, Assay.Works Founder and CEO, commented: "We are excited to partner with 2bind and offer our clients a suite of biophysical assays for hit and lead characterization. The molecular interaction technology perfectly complements our hit-to-lead workflow and the 2bind scientists share our collaborative mindset and approach to client programs. Not to forget, they are a fun team to work with."

Dr. Thomas Schubert, CEO, 2bind added: "You just have to grasp such excellent opportunities! Assay.Works are well-proven experts in assay design, assay development, and large-scale HTS supporting the early stages of drug discovery. Their staff are the highly trained professionals you want to work with. We are glad to now offer our customers access to their HTS and assay development technology!"

https://www.assay.works
https://2bind.com

Media Contacts
Dr. Ralf Schwandner
CEO, Assay.Works GmbH
E-mail: contact@assay.works
Tel: +49 (941) 2000 1240

Dr. Thomas Schubert;
CEO, 2bind GmbH,
E-mail: contact@2bind.com
Tel: +49 (941) 2000 0890

About Assay.Works

Assay.Works is a contract research organization (CRO) providing research services to pharmaceutical/biotech companies and academic organizations in form of fee-for-service work.
Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.
Our service portfolio includes Assay Development, Cell Line Engineering and Production of Cellular Reagents, Bioactivity Assessments, Quantitative Biology Applications, and High-Throughput Screening (HTS).

About 2bind

2bind is a contract research organization (CRO) offering biophysical analytical services in early drug discovery to clients from biotech, pharma, and academic institutions in a fee-for-service business model.
Our mission is to give researchers, developers, and decision makers the power to accelerate and streamline their key research processes. Based on our four core technologies (MicroScale Thermophoresis, nanoDSF, Biolayer Interferometry, and Isothermal Titration Calorimetry), we assist our client in their hit identification, hit validation, and hit characterization projects. Customers benefit from milestone-based projects with clear cost structures as well as rapid and reliable turnaround times. As the sole service provider in the market certified by NanoTemper Technologies for MicroScale Thermophoresis and nanoDSF, we guarantee best data quality. Since our founding, we have completed more than 500 research projects with over 90 clients, including 6 of the top 10 worldwide pharma companies, over 50 SMEs from biotech and pharma, as well as over 25 top-grade academic institutions.

Photos:
https://www.prlog.org/12734958/1
https://www.prlog.org/12734958/2
https://www.prlog.org/12734958/3
End



Like PRLog?
9K2K1K
Click to Share